Human SNP ID | rs153091 |
---|---|
Human chromosome | chr16 |
Human SNP position | 13160099 |
Pig chromosome | chr3 |
Pig SNP position | 31181428 |
PubMed ID | 20195266 |
---|---|
Journal | Mol Psychiatry |
Link | www.ncbi.nlm.nih.gov/pubmed/20195266 |
Study | Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. |
Disease/Trait | Response to antipsychotic treatment |
Initial sample | 421 European ancestry, 214 African American, and 103 cases |
Replication sample | NA |
Region | 16p13.12 |
Chromosome id | chr16 |
Chromosome position | 13160099 |
Reported gene | LOC729993 |
Mapped gene | SHISA9 |
Upstream gene id | |
Downstream gene id | |
SNP gene ids | 729993 |
Upstream gene distance | |
Downstream gene distance | |
SNP risk allele | rs153091-? |
SNPs | rs153091 |
Merged | 0 |
SNP id current | 153091 |
Context | intron_variant |
Intergenic | 0 |
Allele frequency | 0.227 |
P value | 0.000002 |
Pvalue mlog | 5.69897000433601 |
P value text | (perphenazine-triglycerides) |
Or beta | |
%95 Ci | |
Platform | Affymetrix [492900] |
CNV | N |
Mapped trait | response to perphenazine |
Mapped trait URI | http://purl.obolibrary.org/obo/GO_0097334 |
Study accession | GCST000618 |